arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

60 DEGREES PHARMACEUTICALS, INC.

SXTP
$0.90 ▼ -0.05 (-5.61%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
19 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
29
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

60 DEGREES PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $2.4M
Dividend Yield —
Revenue Growth 106.0% ↗
Op. Margin None
ROIC -64.9% ↘
FCF / Share $-0.84 ↗
Trailing P/E —
Price / Book 0.9x
FCF Yield —
Debt / Equity 0.06
info Valuation on last close. End-of-day price, Nov 5, 2026.

19-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$207.90K
↑ +106.0% —
Net Income Profit after all expenses
$-2.26M
↓ -30.6% —
FCF / Share Free cash flow per share
$-0.84
↑ +47.6% —
Long-Term Debt Long-term obligations
$150.03K
— 0.0% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
2
Financial Health →
47
Cash Quality ↑
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 5 years · 19 quarters